Late-life semaglutide treatment extended median lifespan in female mice by 12.4% while improving physical function, memory, and cellular markers of aging. The effect appeared to operate through mechanisms beyond simple caloric restriction, with documented improvements in stem cell function, neurogenesis, and inflammatory signaling.
Key Points
- Median lifespan increased 92 days (742 to 834 days) in treated mice
- Improvements in memory, motor performance, and glucose tolerance documented
- Hematopoietic stem cell aging partially reversed; neurogenesis increased
Longevity Analysis
This research identifies a pharmacological intervention capable of extending lifespan when initiated in late life, a critical variable for translational relevance. The mechanism appears to involve restoration of regenerative capacity in stem cell populations and suppression of chronic inflammatory signaling — two processes central to aging biology. The fact that semaglutide improved functional outcomes alongside lifespan extension, rather than simply extending years lived in decline, suggests the drug may support multiple aging processes simultaneously: preserving cognitive and motor function, maintaining metabolic regulation, and reducing the cellular markers associated with tissue degeneration. The caloric restriction component, while present, does not fully account for the observed benefits, pointing toward additional metabolic or signaling pathways that merit investigation in longer-lived cohorts.
Original published by LifeSpan.io, by Arkadi Mazin.